TearLab Corporation (NASDAQ:TEAR) (TSX:TLB)
- Agreement leverages the combined strength of two leading brands in the management of Dry Eye Disease (DED)
- Co-promotion will utilize positive results from post-market clinical trial of Dry Eye Omega Benefits® to lower osmolarity in dry eye patients enabled by the objective measurement of the TearLab Osmolarity System
SAN DIEGO, Oct. 13, 2016 (GLOBE NEWSWIRE) — TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) (the “Company”) announced today that it has entered into a definitive co-promotion agreement with PRN Physician Recommended Nutriceuticals (PRN), based in Plymouth Meeting, PA, whereby PRN and the Company will jointly promote PRN’s patented omega-3 formulations, including Dry Eye Omega Benefits®. PRN’s marketed omega-3 formulations have been shown to reduce osmolarity levels in dry eye patients utilizing the TearLab Osmolarity System which provides an objective assessment to diagnose and manage patients with DED.
“We are excited to enter into this agreement with PRN, the recognized leader in providing a superior omega-3 formulation to eye care professionals,” said Seph Jensen, Chief Executive Officer of TearLab. “PRN and TearLab are optimal partners as our system, which is the only quantitative and objective osmolarity test on the market, fits well with PRN’s goal of helping doctors manage dry eye patients. The recent peer reviewed publication by the prestigious journal Cornea, demonstrated Dry Eye Omega Benefits® effect on reducing osmolarity in human tears and should provide synergies to accelerate the growth of both PRN and TearLab brands.”
CONTACT: PRN Physician Recommended Nutriceuticals Stefan Schoen Tel: 610-862-0182 ext 102 firstname.lastname@example.org